NCT07194980View on ClinicalTrials.gov

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 20, 2029

Study Completion Date

October 20, 2029

Conditions
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
DRUG

Nemtabrutinib

Given PO

BIOLOGICAL

Lisocabtagene Maraleucel

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER